Mas Zubiri, AliciaHurtado Morillas, ClaraMartínez Rodrigo, AbelOrden Gutiérrez, José AntonioFuente López, Ricardo De LaDomínguez Bernal, Gustavo RamónCarrión Herrero, Francisco Javier2024-01-112024-01-112023-08-02Molina-Rueda F, Fernández-González P, Cuesta-Gómez A, Koutsou A, Carratalá-Tejada M, Miangolarra JC. Test-Retest Reliability of a Conventional Gait Model for Registering Joint Angles during Initial Contact and Toe-Off in Healthy Subjects. Int J Environ Res Public Health. 2021 Feb 15;3(18):1343-521422-006710.3390/ijms241512334https://hdl.handle.net/20.500.14352/92565Zoonotic leishmaniases are a worldwide public health problem for which the development of effective vaccines remains a challenge. A vaccine against leishmaniases must be safe and affordable and should induce cross-protection against the different disease-causing species. In this context, the DNA vaccine pHisAK70 has been demonstrated to induce, in a murine model, a resistant phenotype against L. major, L. infantum, and L. amazonensis. Moreover, a chimeric multiepitope peptide, HisDTC, has been obtained by in silico analysis from the histone proteins encoded in the DNA vaccine and has showed its ability to activate a potent CD4+ and CD8+ T-cell protective immune response in mice against L. infantum infection. In the present study, we evaluated the plasmid DNA vaccine pHisAK70 in comparison with the peptide HisDTC (with and without saponin) against L. major and L. infantum infection. Our preliminary results showed that both formulations were able to induce a potent cellular response leading to a decrease in parasite load against L. infantum. In addition, the DNA candidate was able to induce better lesion control in mice against L. major. These preliminary results indicate that both strategies are potentially effective candidates for leishmaniases control. Furthermore, it is important to carry out such comparative studies to elucidate which vaccine candidates are the most appropriate for further development.engAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/journal articlehttps://www.mdpi.com/journal/ijmsopen access616.993.161636.09:615.37Leishmania vaccineMulti-epitope peptide vaccineDNA vaccineLeishmania immunologyCiencias Biomédicas32 Ciencias Médicas